Summary
Bristol-Myers Squibb Company (BMY) filed an 8-K on July 27, 2022, to report its financial results for the second quarter of 2022. The filing includes the earnings press release, supplemental financial information, and a presentation that was discussed during their investor conference call. While the specific financial figures are not detailed within the 8-K itself, these accompanying documents are crucial for investors to understand the company's performance, strategic initiatives, and outlook. Investors should review the furnished exhibits, particularly the Earnings Press Release and Supplemental Information, to gain insights into BMY's revenue, profitability, and any forward-looking statements. The presentation material provides further context on financial and operating initiatives. It's important to note that some of the presented information may be non-GAAP, and reconciliations to GAAP measures are available in the supplemental information.
Key Highlights
- 1BMY filed an 8-K on July 27, 2022, to announce its Q2 2022 financial results.
- 2The filing includes the Q2 2022 earnings press release (Exhibit 99.1).
- 3Supplemental financial information is provided as Exhibit 99.2.
- 4A presentation on financial and operating initiatives is included as Exhibit 99.3.
- 5These documents are essential for investors to assess the company's recent performance and strategic direction.
- 6The filing notes the use of non-GAAP financial information, with reconciliations provided in the supplemental materials.
- 7The information furnished under Item 7.01 is not considered 'filed' for certain regulatory purposes.